Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation A serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial by Weissman, Neil J. et al.
FP
R
A
U
N
J
M
J
W
S
W
I
F
R
s
n
N
V
¶
M
E
B
H
N
C
Y
T
o
t
r
2
Journal of the American College of Cardiology Vol. 45, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
POCUS ISSUE: DRUG-ELUTING STENTS: TAXUS-IV
olymer-Based Paclitaxel-Eluting Stents
educe In-Stent Neointimal Tissue Proliferation
Serial Volumetric Intravascular
ltrasound Analysis From the TAXUS-IV Trial
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OBJECTIVES The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate
the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and
late incomplete stent apposition.
BACKGROUND The TAXUS-IV trial demonstrated that the slow-release, polymer-based, paclitaxel-eluting
stent reduces angiographic restenosis and the need for repeat revascularization procedures.
Serial IVUS studies reveal details of the pattern of vascular responses provoked by stent
implantation that provide insight into device safety and efficacy.
METHODS In the TAXUS-IV trial, patients were randomized to the slow-release, polymer-based,
paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp.,
Natick, Massachusetts). As part of a formal substudy, complete volumetric IVUS data were
available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and
at nine-month follow-up.
RESULTS No baseline differences were present in the clinical characteristics or IVUS parameters
between the control and TAXUS groups. At nine-month follow-up, IVUS lumen volumes
were larger in the TAXUS group (123  43 mm3 vs. 104  44 mm3, p  0.005), due to a
reduction in neointimal volume (18  18 mm3 vs. 41  23 mm3, p  0.001). Millimeter-
by-millimeter analysis within the stent demonstrated uniform suppression of neointimal
growth along the entire stent length. Late lumen loss was similar at the proximal edge of the
stent between the two groups, and reduced with the TAXUS stent at the distal edge (p 
0.004). Incomplete stent apposition at nine months was observed in only 3.0% of control and
4.0% of TAXUS stents (p  0.12).
CONCLUSIONS Polymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tissue
proliferation, and do not result in late incomplete stent apposition. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.0782005;45:1201–5) © 2005 by the American College of Cardiology Foundation
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Iecent studies of paclitaxel-eluting and sirolimus-eluting
tents have reported dramatic reductions of in-stent reste-
osis for de novo lesions compared to comparable bare-
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004, accepted October 4, 2004.etal stents based on angiographic assessments (1–4).
owever, two-dimensional angiographic parameters pro-
ide insight limited to luminal characteristics. Volumetric
ntravascular ultrasound (IVUS) provides complementary
nformation regarding the extent and distribution of neoin-
ima, arterial remodeling, vascular responses at the edges, and
tent apposition (3,4); the TAXUS-IV is the largest prospec-
ive, randomized, multicenter trial of the polymer-based, slow-
elease paclitaxel-eluting TAXUS stent (2). In the current
rospective study, we performed serial IVUS studies in a subset
f patients enrolled in the TAXUS-IV trial to evaluate vascular
esponses after TAXUS stent implantation.
ETHODS
n the TAXUS-IV trial, 1,314 patients at 73 U.S. centers
ndergoing stent implantation of single de novo lesion (2.5
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The TAXUS-IV IVUS Substudy April 19, 2005:1201–5o 3.75 mm in diameter and 10 to 28 mm in length by visual
stimation) were randomized to receive either the polymer-
ased, paclitaxel-eluting TAXUS stent or an identical bare-
etal EXPRESS stent (Boston Scientific Corp., Natick,
assachusetts). Details of the overall study design and
linical results have been published previously (2). The study
as approved by the institutional review board of each
articipating institution. Eligible patients provided written
nformed consent.
The current IVUS analysis represents the results of a formal
respecified substudy of 268 patients at 28 centers, designed to
ecruit a representative cohort. Clinical sites were selected
ased on their IVUS experience, volume, and willingness to
nroll all study patients. Intravascular ultrasound was per-
ormed immediately after stent implantation and at nine-
onth follow-up in all patients at the IVUS substudy sites
ntil the prespecified enrollment was obtained.
VUS imaging and analysis. Intravascular ultrasound im-
ging was performed after intracoronary administration of
.1 to 0.2 mg nitroglycerin using motorized pullback (0.5
m/s) and contemporary, commercial scanners. Images
ere continuously recorded throughout the stent and at
east 5 mm distal and proximal to the stent. Images were
ecorded onto SVHS videotape or digitally onto CD or MO
isc and analyzed at an independent core laboratory at the
ashington Hospital Center (Washington, DC). All IVUS
ore lab analyses were performed blinded to treatment arm
TAXUS vs. bare-metal stent), and adequacy of the image
or analysis was determined before unblinding the data.
Using computerized planimetry (Tapemeasure, Indec
nc., Mountain View, California), the reference segment
xternal elastic membrane (EEM), stent, and lumen were
easured every millimeter within the stent and 5 mm
roximal and distal to each stent edge. Neointima was
alculated as stent minus lumen measures. To correct for
ifferent stent lengths, because all stents were at least 16 mm
n length, the proximal and distal 7 mm of each stent (14
Abbreviations and Acronyms
EEM  external elastic membrane
IVUS  intravascular ultrasound
able 1. Selected Baseline Clinical and Angiographic Characteris
Entire Study Popu
IVUS Subgroup
(n  268)
Not in IV
Subgro
(n  1,0
ge (yrs) 62.5  10.9 62.5  1
ale gender 71.6% 72.2%
iabetes mellitus 28.0% 23.2%
eference vessel diameter (mm) 2.76  0.52 2.75  0
aximum stent diameter (mm) 3.01  0.38 3.07  0
esion length (mm) 11.82  4.80 13.77  6
tudy stent/lesion length ratio 1.84  1.08 1.84  0VUS  intravascular ultrasound.m total) were aligned and reported. Volumes were calcu-
ated using Simpson’s rule, and baseline and follow-up
mages were aligned using the stent edge. Volumes were
alculated only if the vascular interface was visualized every
illimeter throughout the stent. Incomplete stent apposi-
ion was defined as a separation of at least one stent strut
rom the intimal surface of the arterial wall; incomplete
pposition at nine months was considered “late-acquired” if
t was not present after implantation (5). The primary
respecified end point of this analysis was the comparison of
ntrastent neointimal volume at follow-up between control
nd TAXUS stents.
tatistical analysis. Anticipating neointimal hyperplasia of
1.3 mm3 (10.7 mm3) in the control group, 200 patients
nrolled provided 80% power to detect a 4.3-mm3 absolute
ecrease in neointimal volume in the TAXUS group, a
elative 20% reduction. Thus, 268 patients were prespecified
or enrollment to allow for 25% attrition due to noncom-
liance with invasive follow-up procedures, IVUS technical
ailures, and suboptimal IVUS quality.
Data are presented as frequencies or mean  1 SD.
omparisons between control and TAXUS stents were
erformed with two-tailed, unpaired t tests for continuous
arameters, paired t tests for change from post-procedure to
ollow-up, and Fisher exact test for categorical variables.
ignificance was set at alpha of 0.05.
ESULTS
f the 268 patients in the IVUS substudy, 199 (74.4%)
eturned for the nine-month angiographic follow-up and
ad IVUS performed. Volumetric analysis was performed
nly on IVUS images with a consistent pullback and
dequate image quality for every millimeter throughout the
tent. After excluding 29 patients for inadequate pullback or
oor image quality, volumetric analysis was possible in 170
atients, including 88 and 82 patients receiving TAXUS
nd control stents, respectively. There were no significant
ifferences in key baseline clinical characteristics between
atients in and not in the IVUS substudy, or between the
AXUS and control groups within the IVUS substudy
Table 1). Lesion and stent length were shorter in the
IVUS Volumetric Analysis Population
p Value
TAXUS
(n  88)
Control
(n  82) p Value
1.00 63.1  11.8 60.3  9.9 0.10
0.88 78.4% 70.7% 0.29
0.11 29.5% 24.4% 0.49
0.88 2.76  0.49 2.86  0.59 0.24
0.024 3.02  0.39 3.07  0.38 0.39
0.0001 12.45  5.20 11.42  4.25 0.16
0.95 1.85  1.02 1.94  1.49 0.63tics
lation
US
up
46)
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April 19, 2005:1201–5 The TAXUS-IV IVUS SubstudyVUS substudy due to enrollment in the earlier phases of
he trial.
n-stent neointimal suppression. Intravascular ultrasound
olumetric measures appear in Table 2. Post-implantation
essel, stent, and lumen volumes were similar in the control
nd TAXUS groups. At nine-month follow-up, vessel and
tent volumes were again similar between the control and
AXUS groups, but TAXUS patients had significantly
arger lumens and reduction in neointimal volume. As a
esult, the percent net volume obstruction was reduced from
9.4  14.0% for the bare-metal control stent to 12.2 
2.4% with the TAXUS stent (p 0.001). The reduction in
eointima was uniform throughout the length of the stent;
he mean neointimal area was lower in the TAXUS group
or each millimeter of analysis within the stent (p  0.01)
Fig. 1). Overall vessel volumes were similar between
AXUS and control both at baseline and follow-up. How-
ver, positive remodeling assessed as the absolute increase in
he EEM volume over time tended to be slightly more
rominent with the TAXUS stent (7.66  48.64 mm3 vs.
12.29  36.05 mm3, respectively, p  0.064).
dge analysis. In the 5-mm segment proximal to the stent,
ate lumen loss was similar for TAXUS and control for each
f the 5 mm evaluated. In contrast, at the distal edge,
specially within the first 3 mm outside the stent margin,
umen loss was lower for the TAXUS stent (Fig. 1).
ncomplete apposition. As seen in Figure 2, incomplete
tent apposition was infrequent and comparable for TAXUS
nd control groups. Notably, there was only one case of
ate-acquired incomplete apposition with the TAXUS stent,
hich was focal (1 quadrant in circumference and1 mm
n length), compared to two cases with control stents (p 
.62). No episode of incomplete apposition documented by
VUS was associated with a major adverse cardiac event.
ISCUSSION
he current IVUS substudy from the TAXUS-IV trial
emonstrates that polymer-based, slow-release, paclitaxel-
luting stents reduce neointimal tissue proliferation result-
ng in significantly larger in-stent lumen volumes compared
able 2. Volumetric Intravascular Ultrasound Measurements
In-Stent
Control
(n  82)
TAXUS
(n  88) p Value
ost-implantation
Vessel (mm3) 285  125 283  91 0.91
Stent (mm3) 151  56 155  61 0.66
Lumen (mm3) 151  56 155  61 0.68
Neointima (mm3) 0  0 0  0 0.24
ine-month follow-up
Vessel (mm3) 283  97 280  89 0.88
Stent (mm3) 145  51 142  47 0.70
Lumen (mm3) 104  44 123  43 0.0051
Neointima (mm3) 41  23 18  18 0.0001
Net volume
obstruction (%)
29.4  14.1 12.2  12.4 0.0001o bare-metal stents. These results are concordant with the
g
0linical and angiographic findings from the TAXUS-IV
rial showing enhanced freedom from clinical and angio-
raphic restenosis with the TAXUS stent (2).
The degree of neointimal hyperplasia seen in the control
tent (29.4%) is similar to other bare-metal stents, which
as ranged from 25% to 35% in prior reports (1,3,6–8). The
bserved reduction in neointimal net volume obstruction
ith the TAXUS stent to 12.2% in this study is also
onsistent with the findings from the TAXUS-I (14.8%)
igure 1. Change in vessel (A), plaque (B), and lumen (C) area from
ost-procedure to nine months for TAXUS and the bare-metal control
roups in the stented segments and the edges. Measurements were made
very 1 mm, and baseline and follow-up measurements are aligned to the
tent edges. Results are reported for the proximal and distal 7 mm of each
tent to correct for differences in stent length. Within the stent, neointima
rowth is displayed in panel B rather than plaque outside the stent. *p 
.05; p  0.01; #p  0.001.
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The TAXUS-IV IVUS Substudy April 19, 2005:1201–5nd TAXUS-II (7.8%) trials, which were completed with
ifferent investigator pools and core labs, indicating com-
arable efficacy in different patient and lesion types (1,7).
In contrast, sirolimus-eluting stents have been character-
zed in prior IVUS substudies by the near absence of
easurable in-stent tissue (3,4). Yet from currently available
ata, the clinical efficacy (target lesion and vessel revascu-
arization) of paclitaxel- and sirolimus-eluting stents ap-
ears roughly comparable, suggesting that accumulation of
he small amount of in-stent neointima produced with the
AXUS stent is below the threshold of physiologic signif-
cance in most patients.
In the present study, the frequency of late incomplete
tent apposition with the TAXUS stent was comparable to
he control bare-metal stent, also consistent with prior
tudies with paclitaxel-eluting stents (1,7). In contrast, the
ncidence of late incomplete apposition with the sirolimus-
luting stent has ranged from 19% to 21% compared to 4%
o 9% for bare-metal stents (3,4,6). The slight excess
mount of neointimal hyperplasia with paclitaxel-eluting
ompared to sirolimus-eluting stents may fill in gaps present
ither immediately after the procedure, or emerge from
ositive remodeling during the follow-up period. While the
ccurrence of late incomplete stent apposition has not been
efinitively linked to adverse cardiac events (9), patients
ho develop major adverse events during follow-up often do
ot undergo routine IVUS follow-up, and optimal patient
anagement when stent malapposition is seen is unsettled.
This study confirms and expands the results from previ-
us studies showing no aggravation of edge stenosis (“candy
rapper” phenomenon) with the TAXUS stent. An atten-
ated luminal loss was present at the first millimeters of the
istal edge with the TAXUS stent compared to controls,
imilar to that reported from the TAXUS-II trial (7). The
bsence of a beneficial effect at the proximal edge is at
ariance with the larger TAXUS-IV angiographic substudy,
n which greater angiographic dimensions were present at
oth stent margins with the TAXUS stent. Possible expla-
igure 2. Percentage of patients with incomplete apposition after proced
AXUS group.ations for the differences between angiographic and IVUS
1ndings may be the smaller sample size and more select
ature of patients in the IVUS compared to the angio-
raphic substudy.
Finally, although nine-month vessel volumes were similar
hen comparing the TAXUS and control stents, a trend
as present for slightly more positive remodeling from
aseline to follow-up with the TAXUS stent. This pattern
as also seen in the TAXUS-II trial, with even more
ronounced positive remodeling with the moderate-release
ormulation. It is possible that paclitaxel may inhibit the
nflammatory and or fibrotic responses that affect vessel
emodeling. To date, no adverse consequences have been
scribed to this effect, and serial longitudinal IVUS
ollow-up is being performed in the TAXUS-II trial at two
ears to evaluate the stability and implications of this
bservation.
tudy limitations. Serial IVUS interrogations were per-
ormed in only a small subset of the patients enrolled in the
AXUS-IV trial, which may have introduced selection bias,
hough IVUS substudy patients had similar baseline char-
cteristics compared to the entire study population. It
hould also be recognized that IVUS follow-up tends not to
e performed in severely obstructive vessels, and in patients
ith major adverse cardiac events; as such, follow-up IVUS
epresents a “best-case scenario,” providing complementary
ata to follow-up angiography.
onclusions. The polymer-based, slow-release, paclitaxel-
luting TAXUS stent attenuates vascular responses that lead
o restenosis without adverse edge effects or late incomplete
tent apposition.
eprint requests and correspondence: Dr. Neil J. Weissman, 110
rving Street, NW, Suite EB-5123, Washington, DC 20010.
-mail: Neil.J.Weissman@medstar.net.
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